6 Best Peptides for Muscle Wasting (Cachexia)

What to Know Before Choosing a Peptide for Muscle Wasting (Cachexia)

Cachexia is not the same as being underweight or underfed. It is an active metabolic process, typically tied to cancer, HIV, advanced organ failure, or chronic disease, that degrades muscle tissue faster than nutrition alone can rebuild it. The peptides people turn to for this goal work by opposing the catabolic signals that cachexia amplifies, stimulating the anabolic pathways it suppresses, or both. The biology is real and the clinical need is significant. The evidence, however, is uneven across the field, and that unevenness is worth understanding before reading the entries below.

Every compound in this guide earned its place because people use it or are actively discussing using it for muscle wasting and cachexia. FDA approval status, telemedicine availability, and the depth of the clinical literature were not filters. They are facts stated honestly inside each entry. Some compounds here have phase 2 and phase 3 trial data behind their compound class. Others have strong preclinical rationale and growing community use but no human cachexia trial data as of 2026. The entries draw those distinctions clearly.

The entries are numbered by how prominently each compound appears in the research literature and in real-world use for this specific goal. Those numbers are not a verdict on which compound is superior for any particular person. The right choice depends on underlying condition, health history, and a conversation with a qualified clinician. That personalized step is what the MyPeptidePal app is built to support.

One piece of context that applies to every entry below: a 2025 scoping review identified 87 distinct peptides linked to muscle wasting, but found that only 8.7 percent of human studies in this space were interventional clinical trials. Most human data comes from observational work, and most of that was gathered in populations with type 2 diabetes or heart failure rather than pure cachexia. No peptide is FDA-approved specifically for cancer cachexia or general cachexia as of 2026. Serostim, a form of recombinant human growth hormone, carries the only wasting-specific FDA approval in the class, and that approval covers HIV-associated wasting only. This is a field of enormous clinical need with a research pipeline that has not yet produced a standard-of-care answer.

1. Ipamorelin: The Selective Ghrelin Receptor Agonist for Anabolic Support

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor, the same receptor targeted by the most clinically advanced cachexia drug candidates. It stimulates the pituitary gland to release growth hormone in a pulsatile, physiological pattern, a meaningful distinction from exogenous growth hormone, which overrides the body's own signaling rhythm rather than working within it.

The mechanism ties directly to why ghrelin-pathway compounds are the most studied peptide class for cachexia. When ipamorelin activates ghrelin receptors in the pituitary and hypothalamus, the resulting growth hormone pulse drives IGF-1 production in the liver. IGF-1 then activates the Akt/mTOR/S6K1 pathway, a cellular signaling sequence that tells muscle cells to build protein rather than break it down. That pathway, the Akt/mTOR axis, functions roughly like a molecular accelerator for protein synthesis. Crucially, activated Akt also suppresses the FoxO transcription factors that upregulate MuRF1 and Atrogin-1, the two key enzymes that tag muscle proteins for destruction in cachexia. So the mechanism is not simply "more growth hormone." It is a cascade that directly opposes the protein degradation machinery cachexia activates.

Ipamorelin is also notable for what it does not do. Unlike GHRP-2 or GHRP-6, which also stimulate GH but produce meaningful spikes in cortisol and prolactin alongside it, ipamorelin has high receptor selectivity. Practitioners who use it report far fewer of the hormonal side effects associated with less selective GH secretagogues. The ghrelin receptor agonism also carries a mild appetite-stimulating effect, which is directly relevant in cachexia because the condition involves anorexia alongside muscle loss.

The evidence base for ipamorelin specifically in cachexia is indirect. No published human trial has evaluated ipamorelin alone for this condition as of 2026. The support comes from the ghrelin mimetic compound class, which is the most studied peptide approach for cachexia by a considerable margin. RC-1291, an oral ghrelin mimetic targeting the same receptor, demonstrated improved muscle mass and hand grip strength in a phase 2 trial in cancer cachexia patients. Anamorelin, the most clinically advanced ghrelin mimetic, showed lean body mass increases in phase 3 trials and is approved in Japan for cancer anorexia-cachexia syndrome, though it has not received FDA approval. Ipamorelin shares the receptor mechanism these compounds validated. Whether that class evidence translates directly to ipamorelin at specific use patterns remains untested in formal cachexia trials. It is available as a research chemical and is frequently accessed via peptide clinics in a regulatory gray area in the United States.

2. CJC-1295: The GHRH Analog That Complements Ipamorelin

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, the peptide the hypothalamus naturally produces to signal the pituitary to release GH. Where ipamorelin stimulates GH via the ghrelin receptor pathway, CJC-1295 works through a completely different receptor, the GHRH receptor on the pituitary's somatotroph cells. Activating both pathways simultaneously produces a synergistic GH pulse larger than either compound generates alone, which is why the CJC-1295 and ipamorelin combination is the most referenced GH-stimulating peptide pairing in muscle preservation literature.

Two versions of CJC-1295 exist and they behave quite differently. CJC-1295 without DAC, sometimes called Mod GRF 1-29, has a half-life of roughly 30 minutes, producing a GH pulse that mirrors the body's natural pulsatile pattern. CJC-1295 with DAC attaches to albumin in the bloodstream through a Drug Affinity Complex modification, extending the half-life to approximately six to eight days and producing a sustained elevation in GH rather than discrete pulses. Think of the difference as a brief spike versus a sustained hum. The pulsatile version is considered more physiological; the DAC version trades that for convenience and extended duration.

The mechanism connecting CJC-1295 to cachexia runs through the same GH-to-IGF-1-to-Akt/mTOR pathway that makes the whole GH secretagogue class relevant to muscle wasting. Sustained GH signaling supports protein synthesis, promotes lean mass retention, and the downstream IGF-1 activity directly opposes the FoxO-driven protein degradation cascade that cachexia activates.

The clinical evidence for CJC-1295 specifically in cachexia does not yet exist as a formal trial record. The compound is studied primarily in age-related muscle loss and GH deficiency contexts. The GHRH analog class has regulatory precedent through sermorelin, an older 29-amino-acid GHRH fragment that was FDA-approved for GH deficiency in the 1990s. That precedent confirms the pathway has been formally evaluated in humans, but it does not constitute cachexia trial evidence for CJC-1295 itself. This compound sits in a similar position to ipamorelin: a well-characterized mechanism, a strong biological rationale for use in muscle wasting, and no direct cachexia clinical trial data as of 2026. It is available as a research chemical and accessed through telemedicine in a legally ambiguous context in the US.

3. MK-677: The Oral Ghrelin Mimetic With Appetite Support

MK-677, also known as ibutamoren, occupies an unusual position in this field. It is not technically a peptide. It is an orally active small molecule that acts as a full agonist at the ghrelin receptor, GHS-R1a, the same target as ipamorelin and the same receptor class as anamorelin and RC-1291. In community discussions and practitioner settings it is grouped with peptides consistently, and the mechanism makes that grouping meaningful even if the chemistry does not.

The oral route is the defining practical characteristic. Every other compound in this guide requires subcutaneous injection. MK-677 is taken by mouth, which changes the accessibility picture substantially for people already carrying the physical burden of serious illness. In a cachexia context where patient burden and injection fatigue are real considerations, this is not a minor distinction.

The mechanism follows the same ghrelin-receptor pathway as ipamorelin: GHS-R1a agonism in the pituitary and hypothalamus stimulates GH release, which drives hepatic IGF-1 production, which in turn activates protein synthesis pathways and appetite. MK-677 does not suppress the hypothalamic-pituitary axis the way exogenous GH does, which is a pharmacological advantage for long-duration use. The appetite stimulation it produces tends to be more pronounced and sustained than what shorter-acting ghrelin receptor agonists generate. In a cachexia context, where anorexia is part of the syndrome rather than a side effect to manage, that appetite stimulation is relevant to the therapeutic picture.

Class evidence is real and meaningful. RC-1291 demonstrated both improved muscle mass and improved hand grip strength in a phase 2 cancer cachexia trial. Anamorelin showed lean body mass gains in phase 3 trials and is approved in Japan. MK-677 itself has no published cachexia clinical trial. What exists for this specific compound is human pharmacology data confirming it robustly elevates GH and IGF-1, plus extrapolation from the ghrelin mimetic class. Community-reported use is substantial, particularly in biohacking and performance contexts where its oral route and availability make it widely accessible. One noted concern with prolonged use is the potential for insulin resistance: sustained GH elevation from MK-677 differs from the natural pulsatile pattern and can affect glucose regulation over time. It is available as a research chemical and is not FDA-approved for any indication.

4. IGF-1 LR3: Targeting the Protein Degradation Cascade Directly

IGF-1 LR3 is a modified analog of insulin-like growth factor 1, engineered to extend its half-life from roughly 15 minutes for native IGF-1 to approximately 20 to 30 hours. The modification replaces one amino acid at position 3 and reduces the compound's binding affinity for IGF-binding proteins, the circulating proteins that sequester IGF-1 in the bloodstream and limit how much reaches muscle tissue. The result is a form of IGF-1 that stays active in the body far longer and has greater biological availability at target tissues.

That extended activity has direct relevance to cachexia. Native IGF-1 clears too quickly to maintain meaningful pressure on the degradation pathways cachexia continuously drives. IGF-1 LR3 activates the same IGF-1 receptor but does so with sustained presence rather than a brief window of activity.

The mechanism downstream of IGF-1 receptor activation is among the most validated in muscle biology. IGF-1 binding to its receptor on muscle cells activates the Akt/mTOR/S6K1 pathway, driving protein synthesis and muscle fiber growth. It stimulates satellite cell proliferation, the stem cells responsible for repairing and regenerating muscle tissue, and promotes both hypertrophy and, in some contexts, hyperplasia, meaning new fiber formation rather than just enlargement of existing fibers. Critically for cachexia, activated Akt directly phosphorylates and inactivates the FoxO transcription factors. FoxO is the master regulator that turns on MuRF1 and Atrogin-1, the E3 ubiquitin ligases that tag muscle proteins for destruction via the ubiquitin-proteasome system. In plain terms: IGF-1 LR3 does not just promote muscle building, it directly shuts down the specific molecular machinery that cachexia uses to break muscle down.

The preclinical evidence for this mechanism is strong. Translation to cachexia-specific human trials has been limited. The primary barrier to clinical use involves a serious safety consideration that applies with particular force in cancer cachexia: elevated IGF-1 signaling theoretically promotes cancer cell growth, since many tumor cells express IGF-1 receptors and can exploit the same anabolic pathway being used to rescue muscle. That concern does not make IGF-1 LR3 universally off-limits, but it means the risk-benefit calculation in active malignancy requires careful clinical judgment well beyond what any list article can provide. Adverse events observed in clinical trials of IGF-1 derivatives include edema, myalgia, hypoglycemia, headaches, jaw pain, and altered liver function. IGF-1 LR3 is available only as a research chemical and is not approved for any human use.

5. Follistatin 344: Blocking the Primary Molecular Brake on Muscle Growth

Follistatin is a naturally occurring glycoprotein that functions as an endogenous inhibitor of myostatin, the most powerful negative regulator of muscle mass in the body. Follistatin 344 is the 344-amino-acid isoform produced as a synthetic peptide. Its significance in a cachexia context rests on a direct connection to the pathophysiology: myostatin is one of the primary molecular drivers of muscle wasting, and follistatin blocks it.

Myostatin works by binding to the activin type IIB receptor, ActRIIB, and triggering a signaling cascade through SMAD2 and SMAD3 that ultimately upregulates MuRF1 and Atrogin-1, the same E3 ubiquitin ligases that degrade muscle protein. In cachexia, tumor-derived and inflammation-derived signals push myostatin activity upward, amplifying this degradation cascade. Follistatin 344 binds myostatin directly and prevents it from engaging ActRIIB. Think of myostatin as a brake pedal on muscle growth, and follistatin as the mechanism that lifts that pedal. It also inhibits activin A and other members of the TGF-beta superfamily that feed into the same catabolic signaling network.

The therapeutic concept is validated at the drug-development level. Bimagrumab, a monoclonal antibody that traps activins and myostatin by blocking ActRIIB, targets exactly this pathway and has been investigated in cachexia clinical trials. A pharmaceutical-grade compound pursuing the same mechanism in formal trials confirms this pathway is considered a legitimate therapeutic target by mainstream clinical research, not only by the peptide community.

No direct clinical trials of Follistatin 344 peptide for cachexia have been published as of 2026. The evidence is preclinical and mechanistic: strong rationale based on myostatin's centrality to the wasting cascade, validated indirectly through drug candidates that hit the same target, but without a human trial record for the peptide itself. The compound is available only as a research chemical and is not obtainable through telemedicine. Human safety data is limited. Theoretical concerns include systemic effects from broad myostatin inhibition across organ systems where myostatin plays regulatory roles, immunogenicity risk from antibody formation against the peptide, and, as with other anabolic compounds, a theoretical concern about cancer promotion in an already malignant environment. Community discussion of follistatin 344 for muscle preservation exists primarily in advanced bodybuilding and experimental contexts, where users acknowledge its speculative status while pointing to the mechanistic logic.

6. Gotratix: Community-Referenced Muscle Anabolic With Limited Published Data

Gotratix appears in community discussions of anabolic peptides for muscle preservation and was identified as commonly referenced in this context. The honest account of the available evidence is brief: published scientific literature, clinical trial records, and regulatory filings for a compound under this specific name are extremely limited as of 2026. No mechanism studies, pharmacokinetic data, or clinical trial records for Gotratix were returned by the research process used to build this article.

It is possible that Gotratix is a brand name or regional market name for a compound that carries a different research designation. It is also possible that it is a recently introduced research compound whose peer-reviewed record has not yet accumulated. Either scenario produces the same honest situation for the reader: the evidence here is experiential rather than clinical. Community-reported interest in Gotratix in muscle-building and anti-wasting contexts is what earned it a place in this guide. The inclusion criterion for this list asks whether people are using or discussing a compound for the goal, not whether it has cleared a clinical evidence bar, and the answer for Gotratix is yes.

If you have encountered Gotratix in a protocol context or are researching it specifically, the appropriate next step is to verify what compound it actually corresponds to at the molecular level and what peer-reviewed data, if any, exists under that name or a synonym. A physician or qualified clinician familiar with experimental peptides is the right resource for evaluating a compound whose published record is this thin, particularly in the context of a serious condition like cachexia where the stakes of an uninformed choice are high.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for muscle wasting or cachexia?

One compound, Serostim, a form of recombinant human growth hormone, carries FDA approval for wasting, but that approval is limited to HIV-associated wasting and does not extend to cancer cachexia or other forms of the condition. No peptide or small molecule is FDA-approved specifically for cancer cachexia or general cachexia in the United States or Europe as of 2026. The field has active clinical development, including phase 2 trials for TCMCB07 and the broader ghrelin mimetic class, but none of these have reached approved status.

Is it safe to use GH secretagogues like ipamorelin or MK-677 alongside active cancer?

This question requires a direct conversation with an oncologist rather than a list article. The concern is real: compounds that elevate GH and IGF-1, including ipamorelin, CJC-1295, and MK-677, theoretically could stimulate the growth of cancer cells that express IGF-1 receptors, which many do. Whether that theoretical risk outweighs the potential benefit of preserving muscle mass in a specific patient's situation is a clinical judgment that depends on cancer type, stage, treatment plan, and individual biology. Anyone with active malignancy should treat the safety question around anabolic peptides as a medical conversation, not a self-research decision.

How does cachexia differ from regular muscle loss, and why does it matter for peptide selection?

Cachexia is driven by active inflammatory and catabolic signaling, typically from a tumor or chronic disease, that breaks down muscle faster than nutrition can replace it. Regular muscle loss from disuse or aging responds well to nutrition and exercise because the cellular repair machinery is intact. Cachexia involves the hijacking of that machinery by molecular signals like myostatin, TNF-alpha, and GDF-15. That distinction matters for peptide selection because the most rationally designed compounds for cachexia work by blocking those catabolic signals specifically, as follistatin 344 does with myostatin, rather than simply adding anabolic signal on top of an ongoing degradation process.

Can peptides replace nutrition and resistance training in cachexia?

No, and the research is consistent on this point. Even the most promising investigational cachexia compounds in formal trials are evaluated alongside nutritional support, not instead of it. A caloric surplus and some form of resistance-based physical activity, adapted to what an individual's condition allows, remain foundational. Peptides in this context are studied as adjuncts that amplify the anabolic environment nutrition and movement create, not as substitutes for that foundation.

What does the evidence landscape for cachexia peptides actually look like in 2026?

The landscape is promising in terms of mechanistic rationale but underdeveloped in terms of human trial data. A 2025 scoping review identified 87 distinct peptides linked to muscle wasting but found that only 8.7 percent of human studies in this space were interventional clinical trials. Most human data comes from observational work in populations with type 2 diabetes or heart failure rather than pure cachexia. The most clinically advanced ghrelin mimetic, anamorelin, showed lean body mass gains in phase 3 trials and is approved in Japan, which represents the strongest proof of concept for the class. For the other compounds in this guide, the honest picture is strong biological rationale and limited direct human cachexia trial data.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for muscle wasting and cachexia in one place.